Prognosis of the surgical treatment of patients with non-small cell lung cancer (NSCLC) - Relation to DNA ploidy

European Journal of Cardio-thoracic Surgery

Volumn 23, Issue 6, 2003, Pages 870-877

  Gawrychowski, Jacek ^a   Lackowska, Bozena ^b   Gabriel, Andrzej ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

^b INSTITUTE OF ONCOLOGY   (Poland)

Author keywords

DNA ploidy; Follow up study; Non small cell lung cancer; Surgery

Indexed keywords

ANEUPLOIDY; CANCER SURVIVAL; CELL CYCLE S PHASE; CELL PROLIFERATION; CONFERENCE PAPER; CONTROLLED STUDY; CYTOFLUOROMETRY; DIPLOIDY; HISTOLOGY; HUMAN; LUNG NON SMALL CELL CANCER; MEDICAL ASSESSMENT; MEDICAL EXAMINATION; PLOIDY; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROGNOSIS; RECURRENT DISEASE; SQUAMOUS CELL CARCINOMA; SURGICAL TECHNIQUE; TUMOR VOLUME;

ADENOCARCINOMA; ADULT; AGED; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PLOIDIES; PROGNOSIS; REGRESSION ANALYSIS; SURVIVAL RATE;

EID: 0038048077     PISSN: 10107940     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1010-7940(03)00144-1     Document Type: Conference Paper

References (26)

1. Naruke T., Tsuchiya R., Kondo H., Asamura H. Prognosis and survival after resection for bronchogenic carcinoma based on the 1997 TNM-staging classification: the Japanese experience. Ann Thorac Surg. 71:(6):2001;1759-1764.
2. Putnam J.B. Jr. The anatomic basis for lung cancer staging: the end of the beginning? Ann Thorac Surg. 71:(6):2001;1757-1758.
3. Dalquen P., Moch H., Feichter G., Lehmann M., Soler M., Stulz P., Jordan P., Torhorst J., Mihatsch M.J., Sauter G. DNA aneuploidy, S-phase fraction, nuclear p53 positivity, and survival in non-small-cell lung carcinoma. Virchows Arch. 431:(3):1997;173-179.
4. Dazzi H., Thatcher N., Hasleton P.S., Swindell R. DNA analysis by flow cytometry in non-small cell lung cancer: relationship to epidermal growth factor receptor, histology, tumour stage and survival. Respir Med. 84:(3):1990;217-223.
5. Ellis C.N., Burnette J.J., Sedlak R., Dyas C., Blakemore W.S. Prognostic applications of DNA analysis in solid malignant lesions in humans. Surg Gynecol Obstet. 173:(4):1991;329-342.
6. Merkel D.E., McGuire W.L. Ploidy, proliferative activity and prognosis. DNA flow cytometry of solid tumours. Cancer. 65:(5):1990;1194-1205.
7. Kołodziejski L., Niezabitowski A., Gasinska A. Clinical and flow cytometric prognostic factors in surgically treated squamous cell lung cancer. Lung Cancer. 16:(2-3):1997;173-182.
8. Muguerza J.M., Diez M., Torres A.J., Lopez-Asenjo J.A., Picardo A.L., Gomez A., Hernando F., Cayon R., Granell J., Balibrea J.L. Prognostic value of flow cytometric DNA analysis in non-small-cell lung cancer: rationale of sequential processing of frozen and paraffin-embedded tissue. World J Surg. 21:(3):1997;323-329.
9. Sahin A.A., Ro J.Y., El-Naggar A.K., Lee J.S., Ayala A.G., Teague K., Hong W.K. Flow cytometric analysis of the DNA content of non-small cell lung cancer. Ploidy as a significant prognostic indicator in squamous cell carcinoma of the lung. Cancer. 65:(3):1990;530-537.
10. Volm M., Hahn E.W., Mattern J., Muller T., Vogt-Moykopf I., Weber E. Five-year follow-up study of independent clinical and flow cytometric prognostic factors for the survival of patients with non-small cell lung carcinoma. Cancer Res. 48:(10):1988;2923-2928.
11. Graziano S.L. Non-small cell lung cancer. Clinical value of new biological predictors. Lung Cancer. 17:(Suppl. 1):1997;S37-S58.
12. Mountain C.F. A new international staging system for lung cancer. Chest. 89:(Suppl. 4):1986;225S-233S.
13. The Official Statement of Ad-hoc Committee of the Assembly on Clinical Problems (Jett J.R., Feins R., Silvestri G., Stover D., Spiro S., Travis W.). Pretreatment evaluation of non-small cell lung cancer. Am J Respir Crit Care Med. 156:(1):1997;320-332.
14. Broders A.C. Squamous cell epithelioma of the skin. Ann Surg. 73:1921;141-160.
15. Sobin L.H. The World Health Organization's (). Histological Classification of Lung Tumours. A comparison of the first and second editions. Cancer Detect Prev. 5:(4):1982;391-406.
16. Hedley D.W., Friedlander M.L., Taylor I.W., Rugg C.A., Musgrove E.A. Method for analysis of cellular DNA content of paraffin-embedded pathological material using flow cytometry. J Histochem Cytochem. 31:(11):1983;1333-1335.
17. Shankey T.V., Rabinovitch P.S., Bagwell B., Bauer K.D., Duque R.E., Hedley D.W., Mayall B.H., Wheeless L., Cox C. Guidelines for implementation of clinical DNA cytometry. Cytometry. 14:(5):1993;472-477.
18. Ten Velde G.P., Schutte B., Vermeulen A., Volovics A., Reynerds M.M., Blijham G.H. Flow cytometric analysis of DNA ploidy level in paraffin embedded tissue of non-small cell lung cancer. Eur J Cancer Clin Oncol. 24:(3):1988;445-460.
19. Tanaka I., Masuda R., Furuhata Y., Inoue M., Fujiwara M., Takemura T. Flow cytometric analysis of the DNA content of adenocarcinoma of the lung, especially for patients with stage 1 disease with long term follow-up. Cancer. 75:(10):1995;2461-2465.
20. Malara N.M., Sgambato A., Granone P., Flamini G., Margaritora S., Boninsegna A., Cesario A., Galetta D., Yang Q., Cittadini A. Biological characterization of central and peripheral primary non-small cell lung cancers (NSCLC). Anticancer Res. 19:(3B):1999;2249-2252.
21. Zimmerman P.V., Hawson G.A., Bint M.H., Parsons P.G. Ploidy as a prognostic determinant in surgically treated lung cancer. Lancet. 2:(8558):1987;530-583.
22. Ogawa J., Tsurumi T., Inoue H., Shohtsu A. Relationship between tumour DNA ploidy and regional lymph node changes in lung cancer. Cancer. 69:(7):1992;1688-1695.
23. Roberts H.L., Komaki R., Allen P., El-Naggar A.K. Prognostic significance of DNA content in stage I adenocarcinoma of the lung. Int J Radiat Oncol Biol Phys. 41:(3):1998;573-578.
24. Giaretti W. A model of DNA aneuploidization and evolution in colorectal cancer. Lab Invest. 71:(6):1994;904-910.
25. D'Amico T.A., Massey M., Herndon J.E., Moore M.B., Harpole D.H. A biologic risk model for stage I lung cancer; immunohistochemical analysis of 408 patients with the use of ten molecular markers. J Thorac Cardiovasc Surg. 117:(4):1999;736-743.
26. Saleh H.A., Haapaniemi J., Khatib G. Bronchioloalveolar carcinoma. Diagnostic pitfalls and immunocytochemical contribution. Diagn Cytopathol. 18:(4):1998;301-306.